Dr Cecilia Russell

Dr Cecilia Russell

Research Associate

School of Environmental and Life Sciences

Career Summary

Biography

After receiving undergraduate and PhD qualifications from The University of Newcastle, Cecilia worked in industry in the field of veterinary pharmaceuticals, involving large scale active pharmaceutical ingredient (API) synthesis, working with in a regulated (GLP and GMP) environment, and setting up a laboratory to be able to undertake in-house residue studies.

From 2011 Cecilia has been employed as a post-doctoral researcher in Prof. Adam McCluskey's laboratory at the University of Newcastle in a part-time role, while balancing primary caring duties for two children. 

Additionally from semester 1 2018, Cecilia has been engaged in casual academic teaching, covering both long service leave and parental leave.

The primary focus of Cecilia's research is within the field of medicinal chemistry, where the key aim is the development of tool compounds and drugs targeting endocytosis. This process is focused around the development of inhibitors of dynamin GTPase, this protein has been identified as having roles in epilepsy, cancer and neuropathic pain.

Additional areas of research are the development of small compounds as potential new antibiotics with scaffolds that differ from the current compounds in the clinic where the development of resistance is an increasing concern; and the utilisation of flow chemistry instrumentation to stream line the drug discovery and development process.


Qualifications

  • PhD (Chemistry), University of Newcastle
  • Bachelor of Science (Honours), University of Newcastle
  • Bachelor of Science, University of Newcastle

Keywords

  • analytical chemistry
  • compound purification
  • medicinal chemistry
  • organic synthesis
  • quality assurance and control

Fields of Research

Code Description Percentage
030401 Biologically Active Molecules 50
030503 Organic Chemical Synthesis 50

Professional Experience

UON Appointment

Title Organisation / Department
Research Associate University of Newcastle
School of Environmental and Life Sciences
Australia
Casual Academic University of Newcastle
School of Environmental and Life Sciences
Australia
Casual Academic University of Newcastle
School of Environmental and Life Sciences
Australia

Teaching

Code Course Role Duration
CHEM3550 Medicinal and Biological Chemistry
Discipline of Chemistry, University of Newcastle
Lecturer, tutor, lab demonstrator 19/06/2018 - 30/11/2018
CHEM2310 Organic Chemistry
Discipline of Chemistry, University of Newcastle
Lecturer, tutor, lab demonstrator 27/02/2018 - 21/06/2019
CHEM3310 Molecular Organic Synthesis
Discipline of Chemistry, University of Newcastle
Lecturer, tutor, lab demonstrator 27/02/2018 - 21/06/2019
PHAR2202 Drug Design and Discovery
Discipline of Chemistry, University of Newcastle
Lecturer, tutor, lab demonstrator 19/06/2018 - 30/11/2018
CHEM2201 Analytical and Medicinal Chemistry
Discipline of Chemistry, University of Newcastle
Course coordinator, lecturer, tutor, lab demonstrator 19/06/2018 - 30/11/2018
CHEM3590 Chemistry Research Project
Discipline of Chemistry, University of Newcastle
Supervisor 11/06/2019 - 22/11/2019
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Chapter (1 outputs)

Year Citation Altmetrics Link
2017 Russell C, Cossar P, Baker J, McCluskey A, 'Recent Developments in the Use of Flow Hydrogenation in the Field of Medicinal Chemistry', New Advances in Hydrogenation Processes - Fundamentals and Applications, InTech, London (2017)
DOI 10.5772/65518
Co-authors Adam Mccluskey

Journal article (13 outputs)

Year Citation Altmetrics Link
2019 Al Otaibi A, Deane FM, Russell CC, Hizartzidis L, McCluskey SN, Sakoff JA, McCluskey A, 'A methanol and protic ionic liquid Ugi multicomponent reaction path to cytotoxic a-phenylacetamido amides', RSC Advances, 9 7652-7663 (2019) [C1]
DOI 10.1039/c9ra00118b
Citations Scopus - 1Web of Science - 1
Co-authors Adam Mccluskey, Jennette Sakoff
2019 Russell CC, Stevens A, Young KA, Baker JR, McCluskey SN, Khazandi M, et al., 'Discovery of 4,6-bis(2-((E)-benzylidene)hydrazinyl)pyrimidin-2-Amine with Antibiotic Activity.', ChemistryOpen, 8 896-907 (2019) [C1]
DOI 10.1002/open.201800241
Co-authors Adam Mccluskey
2018 Cossar PJ, Russell CC, McCluskey SN, Pope D, Bernhardt PV, McCluskey A, 'Crystal Structure of Ethyl 2,4-Dimethyl-1-phenyl-6-thioxo-1,6-dihydropyrimidine-5-carboxylate: The Product from the Reaction of Ethyl 3-Aminocrotonate, Phenylisothiocyanate and Acetic Anhydride', JOURNAL OF CHEMICAL CRYSTALLOGRAPHY, 48 91-95 (2018) [C1]
DOI 10.1007/s10870-018-0714-6
Citations Web of Science - 1
Co-authors Adam Mccluskey
2018 Ghods A, Gilbert J, Baker JR, Russell CC, Sakoff JA, McCluskey A, 'A focused library synthesis and cytotoxicity of quinones derived from the natural product bolinaquinone', Royal Society Open Science, 5 (2018) [C1]

© 2018 The Authors. Bolinaquinone is a natural product that is a structurally complex, cytotoxic sesquiterpene quinone. A scaffold simplification and focused library approach usin... [more]

© 2018 The Authors. Bolinaquinone is a natural product that is a structurally complex, cytotoxic sesquiterpene quinone. A scaffold simplification and focused library approach using a microwave-assisted Suzuki coupling gave 32 bolinaquinone analogues with good-to-excellent cytotoxicity profiles. Mono-arylbenzoquinones, Library A, were preferentially toxic towards BE2-C (neuroblastoma) cells with growth inhibition (GI50) values of 4¿12 µM; only the 3,4-dimethoxyphenyl 23 and 3-biphenyl 28 variants were broad-spectrum active¿HT29 (colon carcinoma), U87 and SJ-G2 (glioblastoma), MCF-7 (breast carcinoma), A2780 (ovarian carcinoma), H460 (lung carcinoma), A431 (skin carcinoma), Du145 (prostate carcinoma), BE2-C (neuroblastoma), MIA (pancreatic carcinoma) and SMA (spontaneous murine astrocytoma). Library B with a second aryl moiety exhibited broad-spectrum cytotoxicity with MCF-7 cells¿ GI50 values of 5.6 ± 0.7 and 5.1 ± 0.5 µM for 2,5-dimethoxy-3-(naphthalene-1-yl)-6-(naphthalene-3-yl) 33 and 2,5-dimethoxy-3-(biaryl-2-yl)-6-(naphthalene-3-yl) 36, respectively. Similar potencies were also noted with 2,5-dimethoxy-3,6-diphenyl 30 against A2780 (GI50 = 5.9 ± 0.0 µM) and with 2,5-dimethoxy-3-(biaryl-3-yl)-6-(naphthalene-3-yl) 37 against HT29 (GI50 = 5.4 ± 0.4 µM), while the 3,4-dimethoxy mono-aryl analogue 23 exhibited good levels of activity against A2780 (GI50 = 3.8 ± 0.75 µM), the neuroblastoma cell line BE2-C (GI50 = 3 ± 0.35 µM) and SMA (GI50 = 3.9 ± 0.54 µM). Introduction of the amino-substituted Library C gave 2-(naphthalen-1-yl)-5-(naphthalen-3-yl)-3,6-bis(propylamino) 43, with excellent activity against HT29 (0.08 ± 0.0 µM), MCF-7 (0.17 ± 0.1 µM), A2780 (0.14 ± 0.1 µM), A431 (0.11 ± 0.0 µM), Du145 (0.16 ± 0.1 µM), BE2-C (0.08 ± 0.0 µM) and MIA (0.1 ± 0.0 µM).

DOI 10.1098/rsos.171189
Co-authors Jennette Sakoff, Adam Mccluskey
2018 Russell CC, Stevens A, Pi H, Khazandi M, Ogunniyi AD, Young KA, et al., 'Gram-Positive and Gram-Negative Antibiotic Activity of Asymmetric and Monomeric Robenidine Analogues', CHEMMEDCHEM, 13 2573-2580 (2018) [C1]
DOI 10.1002/cmdc.201800463
Citations Scopus - 1Web of Science - 1
Co-authors Adam Mccluskey
2016 Abraham RJ, Stevens AJ, Young KA, Russell C, Qvist A, Khazandi M, et al., 'Robenidine Analogues as Gram-Positive Antibacterial Agents', JOURNAL OF MEDICINAL CHEMISTRY, 59 2126-2138 (2016) [C1]
DOI 10.1021/acs.jmedchem.5b01797
Citations Scopus - 6Web of Science - 7
Co-authors Adam Mccluskey
2016 Lin AJS, Russell CC, Baker JR, Frailey SL, Sakoff JA, McCluskey A, 'A facile hybrid 'flow and batch' access to substituted 3,4-dihydro-2: H -benzo [b] [1,4]oxazinones', Organic and Biomolecular Chemistry, 14 8732-8742 (2016) [C1]

© The Royal Society of Chemistry 2016. We describe a simple flow chemistry approach to libraries of ethyl 3-oxo-2-(substituted-phenylamino)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-c... [more]

© The Royal Society of Chemistry 2016. We describe a simple flow chemistry approach to libraries of ethyl 3-oxo-2-(substituted-phenylamino)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylates (12a-l) and N-ethyl-3-oxo-2-(substituted-phenylamino)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamides (13a-l) in 38-87% yields. This scaffold is poorly described in the chemical literature. Screening against a panel of 11 cancer and one normal cell line showed that the amide linked library 13a-l was devoid of toxicity. Whereas the ester linked analogues 12b, 12c, 12g, 12j and 12l were highly cytotoxic with growth inhibition (GI50) values from 0.34 to >50 µM across all cell lines, with the 2-OH-Ph substituted 12l analogue presenting with sub-micromolar potency against the A2780 (ovarian; 0.34 ± 0.04 µM), BEC-2 (glioblastoma; 0.35 ± 0.06 µM), MIA (pancreas; 0.91 ± 0.054 µM) and SMA (murine glioblastoma; 0.77 ± 0.029 µM) carcinoma cell lines. Interestingly, the U87 glioblastoma cell line showed inherent resistance to growth inhibition by all analogues (GI50 32 to >50 µM) while the A2780 cells were highly sensitive (GI50 3.8-0.34 µM), suggesting that the analogues developed herein may be valuable lead compounds for the development of ovarian carcinoma specific cytotoxic agents. The differences in amide versus ester cytotoxicity was consitent with esterase cleaveage to release the cytotoxic warhead.

DOI 10.1039/c6ob01153e
Citations Scopus - 3Web of Science - 2
Co-authors Jennette Sakoff, Adam Mccluskey
2015 Russell C, Lin AJS, Hains P, Simone MI, Robinson PJ, Mccluskey A, 'An integrated flow and microwave approach to a broad spectrum protein kinase inhibitor', RSC Advances, 5 93433-93437 (2015) [C1]

© 2015 The Royal Society of Chemistry. The protein kinase inhibitor CTx-0152960 (6, 2-((5-chloro-2-((4-morpholinophenyl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide), and the pip... [more]

© 2015 The Royal Society of Chemistry. The protein kinase inhibitor CTx-0152960 (6, 2-((5-chloro-2-((4-morpholinophenyl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide), and the piperazinyl analogue, CTx-0294885 (7, 2-((5-chloro-2-((4-piperazin-1-ylphenyl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide), were prepared using a hybrid flow and microwave approach. The use of flow chemistry approaches avoided the need for Boc-protection of piperidine in the key SNAr coupling with 1-fluoro-4-nitrobenzene. Microwave coupling of 4-morphilinoaniline 8 and 4-(piperazine-1-yl)aniline 9 with 2-(2,5-dichloropyrimidine-4-ylamino)-N-methylbenzamide 10, proved to be the most efficacious route to the target analogues 6 and 7. This hybrid methodology reduced the number of synthetic steps, gave enhanced overall yields and increased atom economy through step reduction and minimal requirement for chromatographic purification, relative to the original batch synthesis approach.

DOI 10.1039/c5ra09426g
Citations Scopus - 5Web of Science - 5
Co-authors Michela Simone, Adam Mccluskey
2004 Hart ME, Chamberlin AR, Walkom CC, Sakoff JA, McCluskey A, 'Modified norcantharidins: synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity', Bioorganic & Medicinal Chemistry Letters, 14 1969-1973 (2004) [C1]
DOI 10.1016/j.bmcl.2004.01.093
Citations Scopus - 80Web of Science - 79
Co-authors Jennette Sakoff, Adam Mccluskey
2003 Ackland S, Bowyer MC, Baldwin ML, Garner JA, Walkom CC, Sakoff JA, McCluskey A, 'Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines', Bioorganic Chemistry, 31 68-79 (2003) [C1]
DOI 10.1016/S0045-2068(02)00524-2
Citations Scopus - 94Web of Science - 82
Co-authors Stephen Ackland, Michael Bowyer, Adam Mccluskey, Jennette Sakoff
2002 McCluskey A, Ackland S, Gardiner E, Walkom CC, Sakoff J, 'The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?', Anti-Cancer Drug Design, 16 291-303 (2002) [C1]
Citations Scopus - 31Web of Science - 26
Co-authors Stephen Ackland, Adam Mccluskey, Jennette Sakoff
2002 McCluskey A, Atherton MA, Walkom CC, Bowyer M, Sim A, Young D, Sakoff J, 'The first two cantharidin analogues displaying PP1 selectivity', Bioorganic & Medicinal Chemistry Letters, 12 391-393 (2002) [C1]
Citations Scopus - 47Web of Science - 44
Co-authors Adam Mccluskey, Michael Bowyer, Mirella Atherton, Jennette Sakoff
2001 McCluskey A, Walkom CC, Bowyer MC, Ackland SP, Gardiner E, Sakoff JA, 'Cantharimides: A new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A', Bioorganic & Medicinal Chemistry Letters, 11 2941-2946 (2001) [C1]
Citations Scopus - 73Web of Science - 69
Co-authors Adam Mccluskey, Stephen Ackland, Michael Bowyer, Jennette Sakoff
Show 10 more journal articles

Conference (1 outputs)

Year Citation Altmetrics Link
2002 Sakoff JA, Ackland SP, Garg MB, Walkom CC, McCluskey A, 'Protein phosphatase 2A, a novel and unexplored anticancer target', EUROPEAN JOURNAL OF CANCER, FRANKFURT, GERMANY (2002)
Co-authors Adam Mccluskey, Jennette Sakoff, Stephen Ackland
Edit

Grants and Funding

Summary

Number of grants 2
Total funding $25,000

Click on a grant title below to expand the full details for that specific grant.


20191 grants / $20,000

Equipment Grant$20,000

Equipment grant used for the purchase of a Biotage Isolera chromatography system

Funding body: PRC for Chemical Biology and Pharmacology, The University of Newcastle

Funding body PRC for Chemical Biology and Pharmacology, The University of Newcastle
Project Team

Cecilia Russell, Adam McCluskey, Jennifer Baker, Kate Prichard, Nicholas O'Brien

Scheme Equipment Support Scheme 2019
Role Investigator
Funding Start 2019
Funding Finish 2019
GNo
Type Of Funding Internal
Category INTE
UON N

20181 grants / $5,000

Small equipment grant$5,000

Small equipment grant: utilised to purchase Anton-Parr microwave reactor

Funding body: PRC for Chemical Biology and Pharmacology, The University of Newcastle

Funding body PRC for Chemical Biology and Pharmacology, The University of Newcastle
Project Team

Cecilia Russell, Adam McCluskey

Scheme PRC small equipment scheme 2018
Role Lead
Funding Start 2018
Funding Finish 2018
GNo
Type Of Funding Internal
Category INTE
UON N
Edit

Research Supervision

Number of supervisions

Completed0
Current2

Current Supervision

Commenced Level of Study Research Title Program Supervisor Type
2019 Masters Assessing the Efficacy of Bispidinones as Novel Pancreatic Cancer Therapeutic Agents M Philosophy (Biological Sc), Faculty of Science, The University of Newcastle Co-Supervisor
2019 Masters Novel Classes of Iminosugars as Glycosidase Inhibitors via a Flow Chemistry Approach M Philosophy (Chemistry), Faculty of Science, The University of Newcastle Co-Supervisor
Edit

Dr Cecilia Russell

Positions

Research Associate
School of Environmental and Life Sciences
Faculty of Science

Casual Academic
School of Environmental and Life Sciences
Faculty of Science

Casual Academic
School of Environmental and Life Sciences
Faculty of Science

Contact Details

Email cecilia.russell@newcastle.edu.au
Phone (02) 49218711

Office

Room C216
Building Chemistry Building.
Edit